Goodrx (GDRX) Stock
Consumer technology platform for prescription drug price comparison. Here's the price, business snapshot, and what's worth knowing about Goodrx in June 2026.
GoodRx Holdings, Inc. (GDRX) runs a consumer-focused platform that helps people compare prescription drug prices, access discount coupons and use telehealth services. The company generates revenue from advertising, transaction fees, and subscription services like GoodRx Gold. With a market capitalisation of about $1.35 billion, GoodRx sits at the intersection of healthcare and consumer technology, offering a potentially scalable model but one that remains sensitive to regulatory changes, pharmacy reimbursement structures and competition. Investors should know that revenue can be cyclical and tied to drug pricing dynamics and healthcare policy. GoodRx’s user base and partnerships are important growth levers, while margins and cash flow depend on how the company balances marketing, innovation and emerging services. This is general educational information and not personalised advice; stock prices can fall as well as rise, so suitability depends on an investor’s goals, timeframe and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GoodRx stock, believing its value could rise significantly in the future.
Financial Health
GoodRx is performing well with strong revenue and profitability, showing solid cash generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AUTOMATIC DATA PROCESSING INC
Provides business process outsourcing and technology services.
AIRBNB INC
Airbnb is a hospitality company that provides a platform for users to list, discover, and book accommodations and experiences around the world.
Accenture
Provides consulting and technology services.
Baskets Featuring GDRX
Pharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published: 14 March 2026
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: 2 September 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: 19 August 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: 5 August 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: 4 August 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: 17 June 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Usage and reach
GoodRx’s monthly active users and partnerships drive traffic and monetisation opportunities, though user growth can be cyclical and competitive.
Revenue mix matters
Income from advertising, transactions and subscriptions provides diversification, but changes in pharmacy pricing or regulation could affect margins.
Policy and competition
Regulatory decisions and rival digital-health offerings can reshape the outlook; investors should weigh potential upside against execution and regulatory risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
